Will Novavax Stock Ever Hit $300 Again?
On Feb. 8 of last year, shares of the coronavirus vaccine developer Novavax (NASDAQ: NVAX) commanded a price near $319, with the market's fervor for its jab feeding more and more into the hype. Of course, if you bought shares of it on that day and held them until now, you'd (unfortunately) be looking at some gnarly losses in excess of 70%. But, as the mantra of long-term investors goes, if you hold on for just a while longer, things just might look up.
To return to $300 from its current level near $90, the company's value would need to rise by over 225%. That's definitely not a swing that's possible in the near term -- or is it?
Image source: Getty Images.
Source Fool.com
